BIOMAT Database Logo BIOMAT Database Logo

[Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia]. 2001

K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Department of Pediatrics, Graduate School of Medicine, Kyoto University.

Twelve children with high-risk acute lymphoblastic leukemia underwent stem cell transplantation (SCT) with a conditioning regimen consisting of busulfan, cyclophosphamide and thiotepa. Eight of them underwent SCT while in complete remission (CR) and the other 4 while not in CR. Three children underwent HLA-matched related bone marrow transplantation (BMT), 7 HLA-matched unrelated BMT, 1 HLA one-locus-mismatched unrelated cord blood cell transplantation, and 1 autologous peripheral blood stem cell transplantation. Grade II-IV acute GVHD was observed in 3 of the 11 allo-SCT cases, while chronic GVHD was seen in 3 of 9 evaluable cases. None of the 12 cases showed thrombotic microangiopathy, and veno-occlusive disease (VOD) was observed in 3. Nine of the patients are alive and disease-free 6-45 months after diagnosis. The event-free survival rate at 3 years was 72.2% for the 12 patients, including 8 of the 9 who received SCT during CR, and 2 of the 4 who did so while not in CR. The other 3 patients died: 2 of disease progression and 1 of VOD with pneumonia. All of those who died had undergone unrelated BMT.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
[Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia].
July 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia.
January 2024, Annals of hematology,
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia.
April 2019, Current hematologic malignancy reports,
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Addition of Thiotepa to Total Body Irradiation and Cyclophosphamide Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia.
November 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia.
October 2021, Blood advances,
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
August 2011, Haematologica,
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
December 2023, Hematology (Amsterdam, Netherlands),
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia.
May 2016, Annals of hematology,
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia.
November 2009, Current opinion in hematology,
K Umeda, and Y W Lin, and K Watanabe, and S Adachi, and I Usami, and Y Akiyama, and M Kubota, and T Nakahata
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.
February 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Copied contents to your clipboard!